Damon Runyon is delighted to announce the unanimous election of Carlos Arteaga, MD, and Levi Garraway, MD, PhD, to its Board of Directors.

An internationally acclaimed expert in the field of breast cancer research, Dr. Arteaga currently serves as Director of the Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center. He is well-regarded for his work in developing targeted therapies for hard-to-treat breast cancers and understanding mechanisms of treatment resistance. Among other distinctions, Dr. Arteaga is a former president of the American Association of Cancer Research, the largest cancer research organization in the world.

As Chief Medical Officer and Head of Product Development at Roche and Genentech, and former Senior Vice President of Global Oncology at Eli Lilly, Dr. Garraway knows what it takes to bring new cancer treatments into the world. He is a celebrated biomedical researcher himself, having played a key role in the development of a genomic testing technology that facilitated the rise of precision medicine worldwide. Prior to his role as an industry leader, Dr. Garraway served as an associate professor of medicine at the Dana-Farber Cancer Institute and Harvard Medical School, where he earned both his degrees.

We look forward to officially welcoming Dr. Garraway and Dr. Arteaga to the Board at its next meeting in June.